SANTA FE, N.M. – July 13, 2021 – OpenEye Scientific, an industry leader in computational molecular design, has named Dr. Giovanna Scapin as its newest addition to its Board of Directors.
Read MoreAchievement Demonstrates OpenEye’s Unparalleled Experience Helping Pharmaceutical and Biotechnology Customers Optimize Computing Workloads
Read More
Orion™ Molecular Design Platform Helps Pharmaceutical, Biotechnology Companies Better Identify, Optimize, and Order Hits and Leads from Mcule’s database
SANTA FE, N.M., & PALO ALTO, Calif. – March 18, 2021 – OpenEye Scientific and Mcule – a leading online marketplace for drug discovery – today announced that OpenEye’s Orion™ molecular design platform now can greatly enhance the ability to search and screen molecules through Mcule’s purchasable compound library.
Read More
Sygnature Accelerates Customers’ Drug Discovery Timelines with Improved Hit Identification, Lead Optimization Capabilities
SANTA FE, N.M., USA, & NOTTINGHAM, UK – 21 January 2021 – OpenEye Scientific and Sygnature Discovery – a world-leading integrated discovery and pre-clinical solutions provider – today announced the adoption of OpenEye’s Orion™ platform to power Sygnature’s computational efforts in molecular design drug discovery solutions.
Read More
OpenEye Scientific is pleased to announce the release of OpenEye Applications and Toolkits 2020.2, which contains several key upgrades and improved performance.
Read MoreAs your team engages in molecular design, you likely are working in a number of disparate applications. As a result, you and your team may have challenges organizing, annotating, or sharing your the data from those applications.
Read More
OpenEye Scientific Helps Beacon Discovery Increase Speed and Improve Activity in Virtual Screening
Read More
OpenEye Scientific is pleased to announce the release of Orion v2020.2 Update.
Orion’s new features will provide more flexibility and speed to your molecular design processes, including the ability to:
SANTA FE, N.M., & NEW YORK, N.Y. – July 30, 2020 – OpenEye Scientific (OpenEye) and CHDI Foundation (CHDI) today announced a research collaboration to identify novel small-molecule therapeutics for Huntington’s disease (HD) utilizing Orion, OpenEye’s cloud-native molecular design platform.
Read More
